WO2020139163A3 - Combinaison de produits antiviraux, ensemble et méthode de traitement sur leur base - Google Patents

Combinaison de produits antiviraux, ensemble et méthode de traitement sur leur base Download PDF

Info

Publication number
WO2020139163A3
WO2020139163A3 PCT/RU2019/001031 RU2019001031W WO2020139163A3 WO 2020139163 A3 WO2020139163 A3 WO 2020139163A3 RU 2019001031 W RU2019001031 W RU 2019001031W WO 2020139163 A3 WO2020139163 A3 WO 2020139163A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
mammal
agent
treatment
group
Prior art date
Application number
PCT/RU2019/001031
Other languages
English (en)
Russian (ru)
Other versions
WO2020139163A2 (fr
Inventor
Роберт Шалвович БИБИЛАШВИЛИ
Александр Васильевич КОНОНОВ
Алексей Викторович Кравченко
Анастасия Львовна ХАНДАЖИНСКАЯ
Алина Руслановна СИМОНЯН
Original Assignee
Общество С Ограниченной Ответственностью "Пролонгированные Лекарства"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Пролонгированные Лекарства" filed Critical Общество С Ограниченной Ответственностью "Пролонгированные Лекарства"
Priority to KR1020217023854A priority Critical patent/KR20210119408A/ko
Priority to BR112021017961A priority patent/BR112021017961A2/pt
Priority to CN201980093074.5A priority patent/CN113473994A/zh
Publication of WO2020139163A2 publication Critical patent/WO2020139163A2/fr
Publication of WO2020139163A3 publication Critical patent/WO2020139163A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Le groupe d'inventions se rapporte au domaine de la médecine et de l'industrie pharmaceutique et notamment à une combinaison pour le traitement de l'infection au VIH contenant (i) un sel ammoniaqué de 5-aminocarbonylphosphanate-3-azido-3-désoxythymidine et (ii) un analogue de cytidine sélection parmi emtricitabine et lamivudine, avec un rapport massique de l'agent (i) à l'agent (ii) de 250:1 et jusqu'à 1:250, un ensemble qui comprend la combinaison spécifiée et les instructions pour son utilisation; et également une méthode de traitement d'une infection par le VIH chez un mammifère, y compris un humain, en administrant à un mammifère qui en a besoin une quantité thérapeutiquement efficace d'une combinaison de l'invention. Le groupe d'inventions permet d'élargir la gamme de préparations antivirales combinées pour traiter l'infection au VIH et pour augmenter l'efficacité d'un tel traitement.
PCT/RU2019/001031 2018-12-27 2019-12-26 Combinaison de produits antiviraux, ensemble et méthode de traitement sur leur base WO2020139163A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020217023854A KR20210119408A (ko) 2018-12-27 2019-12-26 항바이러스제 복합물
BR112021017961A BR112021017961A2 (pt) 2018-12-27 2019-12-26 Combinação de agentes antivirais, kit e método de tratamento com base nos mesmos
CN201980093074.5A CN113473994A (zh) 2018-12-27 2019-12-26 抗病毒剂的组合、基于其治疗的试剂盒和方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018147078A RU2726210C2 (ru) 2018-12-27 2018-12-27 Комбинация противовирусных средств, набор и способ лечения на ее основе
RU2018147078 2018-12-27

Publications (2)

Publication Number Publication Date
WO2020139163A2 WO2020139163A2 (fr) 2020-07-02
WO2020139163A3 true WO2020139163A3 (fr) 2020-08-27

Family

ID=71130174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2019/001031 WO2020139163A2 (fr) 2018-12-27 2019-12-26 Combinaison de produits antiviraux, ensemble et méthode de traitement sur leur base

Country Status (5)

Country Link
KR (1) KR20210119408A (fr)
CN (1) CN113473994A (fr)
BR (1) BR112021017961A2 (fr)
RU (1) RU2726210C2 (fr)
WO (1) WO2020139163A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022237405A1 (en) * 2021-03-15 2023-11-02 Transposon Therapeutics, Inc. Line-1 inhibitors to treat cns and systemic diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2331420C2 (ru) * 2005-12-08 2008-08-20 Роберт Шалвович Бибилашвили Противовирусное средство (варианты) и способ лечения на его основе
RU2441016C1 (ru) * 2010-05-28 2012-01-27 Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" Соли 5'-аминокарбонилфосфоната 3'-азидо-3'-дезокситимидина, являющиеся селективными ингибиторами продукции вируса иммунодефицита человека вич-1
US8716264B2 (en) * 2003-01-14 2014-05-06 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US20140193491A1 (en) * 2011-05-30 2014-07-10 Cipla Limited Pharmaceutical antiretroviral composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2446169C2 (ru) * 2010-05-28 2012-03-27 Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" Способ получения 5'-аминокарбонилфосфонатов нуклеозидов и способ получения хлорангидрида триметилсилильного эфира этоксикарбонилфосфоновой кислоты
KR101976231B1 (ko) * 2011-10-14 2019-05-07 자크리토에 악치오네르노에 오브쉐스토보 ＂프로이즈보드스트벤노-콤머체스카야 아쏘치아치야 아즈트＂ 인간 면역결핍 바이러스 hiv-1 생산의 선별적인 저해제로서 작용하는 카르바모일 포스폰산 에스테르의 염
CN104884063A (zh) * 2012-10-23 2015-09-02 西普拉有限公司 抗逆转录病毒药物组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716264B2 (en) * 2003-01-14 2014-05-06 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
RU2331420C2 (ru) * 2005-12-08 2008-08-20 Роберт Шалвович Бибилашвили Противовирусное средство (варианты) и способ лечения на его основе
RU2441016C1 (ru) * 2010-05-28 2012-01-27 Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" Соли 5'-аминокарбонилфосфоната 3'-азидо-3'-дезокситимидина, являющиеся селективными ингибиторами продукции вируса иммунодефицита человека вич-1
US20140193491A1 (en) * 2011-05-30 2014-07-10 Cipla Limited Pharmaceutical antiretroviral composition

Also Published As

Publication number Publication date
RU2726210C2 (ru) 2020-07-09
KR20210119408A (ko) 2021-10-05
RU2018147078A (ru) 2020-06-29
BR112021017961A2 (pt) 2021-12-28
WO2020139163A2 (fr) 2020-07-02
CN113473994A (zh) 2021-10-01
RU2018147078A3 (fr) 2020-06-29

Similar Documents

Publication Publication Date Title
HRP20191957T1 (hr) Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba
CY1118059T1 (el) Συνθεσεις αντιλοιμωδων βασει λιπιδιων για αγωγη πνευμονικων λοιμωξεων
CR20220675A (es) Análogos de nucleósido de 1´- ciano y usos de los mismos
MX2019012884A (es) Terapia de combinacion.
MX2012007410A (es) Compuestos antivirales novedosos.
NO20076219L (no) Farmasoytisk formulering med apomorfin for bukkal administrering
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
WO2018089328A8 (fr) Traitement de maladies du snc au moyen de stimulateurs de gcs
CO2021007648A2 (es) 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden
MD20190018A2 (ro) Compoziţie, în particular o compoziţie farmaceutică preventivă şi curativă pe bază de peroxometalat
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
MX2018000240A (es) Metodos para tratar el vhc.
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
WO2020139163A3 (fr) Combinaison de produits antiviraux, ensemble et méthode de traitement sur leur base
MX2020008360A (es) Forma cristalina de bictegravir sodico.
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
Tobie The trypanocidal effect of nucleocidin in vivo
MX2021002936A (es) Uso de recambio plasmatico de bajo volumen para el tratamiento de la enfermedad de alzheimer en etapas temprana y moderada.
WO2014193269A3 (fr) Médicament à base de diindolylméthane et son utilisation pour traiter la grippe et les infections virales respiratoires
HUP0402062A2 (hu) Alkanoil-L-karnitin alkalmazása merevedési zavar kezelésére és ezt tartalmazó gyógyszerkészítmények
GEP20227432B (en) Therapy of high-risk human papillomavirus infections
EA202091903A1 (ru) Кристаллическая форма битегравир-натрия

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021017961

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112021017961

Country of ref document: BR

Free format text: APRESENTAR, EM ATE 60 (SESSENTA) DIAS, RELATORIO DESCRITIVO E DESENHOS, SE HOUVER, CONFORME CONSTA NO DEPOSITO INTERNACIONAL INICIAL PCT/RU2019/001031 DE 26/12/2019, POIS O MESMO NAO FOI APRESENTADO ATE O MOMENTO.

ENP Entry into the national phase

Ref document number: 112021017961

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210910

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 04.11.2021)

122 Ep: pct application non-entry in european phase

Ref document number: 19903163

Country of ref document: EP

Kind code of ref document: A2